Lack of dopaminergic involvement in modalinil, but not amphetamine and methylphenidate, activity in anaesthetized mice and rats: in vivo voitammetry studies

Duteil, J; Séréville, J.E. De; Boer, C.; Rambert, Francis

doi:10.1016/0014-2999(90)94536-7

Cited by 10 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, amphetamine releases catecholamines while methylphenidate is known to inhibit catecholamine uptake resulting in increased levels of dopamine in the nucleus accumbens. Both of these drugs induce stereotyped behavior [31]. One study demonstrated that systemic modafinil decreased γ‐aminobutryic acid (GABA) release in the cerebral cortex and other such sleep‐related brain regions in the rat.…”

Section: Discussionmentioning

confidence: 99%

Modafinil Treatment of Opioid-Induced Sedation

Webster¹,

Andrews²,

Stoddard

2003

Pain Medicine

View full text Add to dashboard Cite

A B S T R A C TStudy Objective. The purpose of this study was to assess the efficacy of modafinil in combating opioid-induced sedation.Design. A 1-year retrospective chart review of all patients receiving modafinil, a wake-promoting agent, to treat opioid-induced sedation. Opioid-induced sedation was measured using Epworth Sleepiness Scale (ESS).Setting. Outpatient, private practice.Patients. Eleven adult patients, six female and five male, being treated with opioids for chronic, nonmalignant pain.Results. A significant decrease was observed between pretreatment and posttreatment ESS measurements during modafinil treatment. Conclusion.The results suggest an improvement in opioid-induced sedation in patients treated for nonmalignant pain.

show abstract

Section: Discussionmentioning

confidence: 99%

Modafinil Treatment of Opioid-Induced Sedation

Webster¹,

Andrews²,

Stoddard

2003

Pain Medicine

View full text Add to dashboard Cite

show abstract

“…18,19 It is neither a direct nor an indirect acting dopamine receptor agonist and is inactive in several preclinical models capable of detecting enhanced dopaminergic activity. 20,21 Modafinil has a differential pattern of regional C-FOS induction in the rat brain versus amphetamines 22 and is believed to work selectively in the areas of the brain involved in the regulation of normal wakefulness. 23,24 This agent does not cause the global activation seen with stimulants.…”

Section: Introductionmentioning

confidence: 99%

Modafinil for the Treatment of Pain-Associated Fatigue

Fishbain¹,

Cutler²,

Lewis³

et al. 2004

J. Of Pain & Palliative Care Pharmacotherapy

View full text Add to dashboard Cite

Fatigue is a symptom that is frequently found in chronic pain patients with low back pain and/or neck pain. At the present time, no specific psychopharmacological treatment for this problem has been identified. Modafinil is a wakefulness-promoting agent that the FDA has approved for the treatment of excessive daytime sleepiness associated with narcolepsy. There have been reports on the use of modafinil for the treatment of fatigue in various neurological syndromes. This literature is reviewed. As such, modafinil treatment was initiated for a patient with severe fatigue associated with chronic low back pain and neck pain. There was dramatic improvement in fatigue and associated function. This case is described. It is the first such case report in the literature. The significance of this finding to the treatment of pain-associated fatigue is discussed.

show abstract

The stimulant effect of modafinil on wakefulness is not associated with an increase in anxiety in mice

1994

View full text Add to dashboard Cite

Modafinil is a new drug used in the treatment of narcolepsy. Its administration in mice induced a dose-dependent increase in locomotor activity. The effects of modafinil were compared with those of dexamphetamine on three tests that assessed the anxiety level (drugs were used at doses which induced a roughly similar stimulation of locomotor activity). Dexamphetamine increased the latency of exploration of a white compartment, increased thigmotaxis in an open-field and decreased the time spent in the open arms of an elevated plus-maze. None of these responses was significantly modified by modafinil. We conclude that modafinil does not share the anxiogenic effects of dexamphetamine.

show abstract

Lack of dopaminergic involvement in modalinil, but not amphetamine and methylphenidate, activity in anaesthetized mice and rats: in vivo voitammetry studies

Cited by 10 publications

References 0 publications

Modafinil Treatment of Opioid-Induced Sedation

Modafinil Treatment of Opioid-Induced Sedation

Modafinil for the Treatment of Pain-Associated Fatigue

The stimulant effect of modafinil on wakefulness is not associated with an increase in anxiety in mice

Contact Info

Product

Resources

About